Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

Conditions: Surgery, Neoadjuvant Chemotherapy, Management, Resectable Pancreatic Cancer

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 50

Sponsor: Minia University

Summary

This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.

Eligibility Criteria

Inclusion Criteria: * Computed tomography (CT) with pancreatic protocol + vascular mapping * Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein. Exclusion Criteria: * Borderline resectable \& locally advanced pancreatic cancer * Tumor at the tail of the pancreas. * Metastatic pancreatic cancer * Unfit patients for surgery.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06978322). StuddyBuddy aggregates publicly available trial information.